SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

The downregulation of ADH4 expression induces hepatocyte apoptosis, thereby contributing to liver fibrosis and the initiation of hepatocellular carcinoma ... target malignant cells while ...

Solute carrier family 25 member 19 (SLC25A19) is a transporter protein of thiamine pyrophosphate across cellular membranes, which is needed as a cofactor for multiple metabolic enzymes and is ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...

This is the highest reported objective response rate of any systemic treatment in unresectable hepatocellular carcinoma, surpassing atezolizumab–bevacizumab (30%) 11 and STRIDE (20%). 13 However, this ...

Tremelimumab has been approved by the FDA in the US for use in tandem with AZ's PD-L1 inhibitor Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), the most ...

The incidence of gastrointestinal cancers varies across Asian American, Native Hawaiian and other Pacific Islander communities, according to a study published March 15 in the journal Gastro Hep ...